Background: Currently, the 5-year survival rate for rectal cancer remains at <60%. The identification of potentially modifiable prognostic factors would be of considerable public health importance. A few studies have suggested associations between smoking and survival in rectal cancer; however, the evidence is inconsistent, and most of these studies were relatively small. In a large populationbased cohort study, we investigated whether smoking at diagnosis is an independent prognostic factor for cancer-specific survival in rectal cancer and whether the association varies by sex, age, or treatment. Methods: Rectal cancers (ICD10 C19-20) diagnosed between 1994 and 2012 were abstracted from the National Cancer Registry Ireland and classified by smoking status at diagnosis. Follow-up was for 5 years or until December 31, 2012. Multivariable Cox proportional hazards models were used to compare cancerspecific death rates in current smokers, ex-smokers, and never smokers. Subgroup analyses by age at diagnosis, sex, and treatment were conducted. Results: A total of 10,794 rectal cancers were diagnosed. At diagnosis, 25% were current smokers, 24% were ex-smokers, and 51% were never smokers. Compared with never smokers, current smokers had a significantly greater rate of death from cancer (multivariable hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.06-1.24), but ex-smokers did not (HR, 1.02; 95% CI, 0.94-1.11). The association was slightly stronger in men (current versus never smokers: HR 5 1.13, 95% CI, 1.02-1.24) than females (HR, 1.05; 95% CI, 0.90-1.23), but the test for interaction was not significant (P 5 .75). The effect of smoking was not modified by age or receipt of tumor-directed surgery, radiotherapy, or chemotherapy. Conclusions: Rectal cancer patients who smoke at diagnosis have a statistically significant increased cancer death rate. Elucidation of the underlying mechanisms is urgently required. Cancer 2017;123:2543
INTRODUCTION
Although rectal cancer outcomes have improved over time, the average 5-year relative survival rate for patients diagnosed between 2000 and 2007 in Europe was only 56%. 1 In addition, considerable variation in outcomes is evident. For example, within Europe, the 5-year relative survival rate ranges from 38% to 63%. 1 Moreover, there is variation within as well as between countries, with poorer outcomes observed among patients who are older, are more socio-economically deprived, and live in rural areas. [2] [3] [4] The identification of potentially modifiable prognostic factors would be of considerable public health importance.
In this regard, there is growing interest in the influence of lifestyle behaviors on cancer survival (see, for example, the 2014 report by World Cancer Research Fund International 5 ). The US Surgeon General decided recently that there is sufficient evidence to consider smoking as a causal factor for poorer cancer outcomes. 6 Prediagnostic smoking is a causal factor for developing colorectal cancer and, in some studies, the relationship is stronger and more consistent with rectal cancer than colon cancer. 7, 8 Less is known about whether smoking influences survival among individuals with rectal cancer. A recent systematic review identified 15 studies of smoking and survival in colorectal cancer 9 and estimated a combined all-cause hazard ratio (HR) for current smokers of 1.26 (95% confidence interval [CI], 1.15-1.37). However, only 7 studies have reported separately on rectal cancer, [10] [11] [12] [13] [14] [15] [16] and only 2 of those studies found significant associations between current smoking and rectal cancer mortality. 10, 13 Two studies suggested that the effect of smoking on mortality/survival was stronger in older patients, 11, 15 and 3 studies suggested that it was limited to, or stronger in, men 13, 15, 16 ; however, most of these analyses included all colorectal cancers. In addition, the study sizes were modest: the number of rectal cancer cases (or deaths) ranged from 121 to 1514. Moreover, only 1 study identified subjects using a populationbased registry, but this study focused primarily on younger patients. 11 Finally, despite evidence that smoking can adversely affect post-resection outcomes (see, for example, Walter et al, 9 Nickelsen et al, 17 and Richards et al 18 ) and perhaps also chemoradiation response, 19 no studies appear to have considered whether treatment modifies associations between smoking and survival.
We conducted a large population-based cohort study to investigate whether smoking status at diagnosis is an independent prognostic factor for cancer-specific survival among incident rectal cancers. Our secondary goals were to determine whether this association varies by sex, age, or treatment.
MATERIALS AND METHODS

Data
Data were derived from the National Cancer Registry Ireland (www.ncri.ie), which records all incident cancers in Ireland. Registration completeness exceeds 97%. 20 Trained tumor registration officers collect patient, tumor, and treatment details for each registration following internationally accepted registration and coding conventions. Patients' smoking status at diagnosis, as recorded in their hospital records, is also collected.
Rectal cancers diagnosed between 1994 and 2012 (ICD10 C19-20; n 5 13,857) were abstracted from the registry. Cases were excluded if they were identified from death certificates only (n 5 140), had another cancer (other than a non-melanoma skin cancer) diagnosed since January 1, 1994 (n 5 2014), or had a tumor morphology other than adenocarcinoma (n 5 909).
Death ascertainment, achieved by linking registrations to death notifications, was complete to December 31, 2012. Rectal cancer-specific deaths were defined as those for which the underlying cause of death was coded as cancer: at the same diagnosis site; of the same body system; of another specified site; or of unknown site. 21 Individuals were categorized by whether they had undergone 1) tumor-directed surgery, 2) radiotherapy, or 3) chemotherapy within a year of diagnosis. Summary stage at diagnosis was defined using the Union for International Cancer Control classification. Address at diagnosis was used to assign each patient to a deprivation category, ranging from least deprived (1) to most deprived (5) based on a score derived from 2002 census variables. 22 Other socio-demographic variables were derived from National Cancer Registry Ireland records.
Smoking status at diagnosis was classified as: never smoker, ex-smoker (ie, smoked at least once every month in the past but not in the previous year), and current smoker (ie, smoked at least once every month in the previous year). Smoking at diagnosis was missing for 23% (n 5 2512) of cases, and missingness varied by patientrelated, tumor-related, and treatment variables (Supporting Table 1 ). Tumor stage and grade, both important prognostic factors, 23, 24 were incomplete or missing for 9% (n 5 987) and 13% (n 5 1430) of cases, respectively. Missing data items in these three fields were populated using multiple imputation by chained equations. 25 Fifty datasets were generated, in which missing values for smoking status, cancer grade, and cancer stage were imputed using multinomial logistic regression (Supporting Table  2 ). Multiple imputation produces less biased estimates than complete case analysis under a range of missing data scenarios and, under other scenarios, is more efficient than complete case analysis. 26 
Statistical Analysis
The primary analyses were based on the dataset containing the imputed data. The initial analysis included all cases. Analyses were repeated for subgroups defined by sex, age at diagnosis, treatment, diagnostic period, and disease stage. Survival time was computed from the date of diagnosis to date of death, 5 years of follow-up, or the censoring date (December 31, 2012), whichever occurred first. Non-cancer-related deaths were censored when computing cancer-specific survival. The characteristics of individuals classified as never smokers, ex-smokers, and current smokers at diagnosis were compared using chisquare tests. Unadjusted and multivariable hazard ratios for cancer-specific death within 5 years by smoking status were computed using Cox proportional hazard regression. Hazard ratio estimates from the 50 imputed datasets were combined to give a single estimate and standard error adjusted for inter-and intra-imputation variance following Rubin's rules. 27 A backward stepwise approach was used to identify patient-related and clinical confounders, with variables retained at P < .05 (Wald test). The hazards for age group (categorized as <55, 55-64, 65-74, and 75 years), disease stage, and treatment were not proportional, so these variables were fitted as strata. The same approach was used to build the stratified models. In these analyses, age group was categorized as <65/65 years; treatment as Original Article cancer-directed surgery yes/no, radiotherapy yes/no, and chemotherapy yes/no; disease stage as loco-regional (stage I/II/III)/metastatic (IV); and period as 1994-2006/2007-2012 . Interactions between smoking and these variables were tested by fitting cross-product terms. To aid interpretation, we generated curves of cumulative incidence of cancer-specific deaths and deaths due to other causes by smoking status. Throughout, a 2-sided P value of .05 was considered statistically significant.
Sensitivity analyses were conducted in the "complete case" dataset. Unadjusted and adjusted hazard ratios by smoking status were computed, restricting consideration to patients without missing data for smoking status, disease stage, or disease grade (n 5 6829). A further sensitivity analysis was undertaken using competing risk regression in both the imputed and complete case datasets.
RESULTS
Primary Analyses: Multiple Imputed Dataset
A total of 10,794 rectal cancers were included. After imputation, 51% were classified as never smokers at diagnosis, 24% were classified as ex-smokers, and 25% were classified as current smokers (Table 1) . Two-thirds were male; 40% were under 65 at diagnosis; almost four-fifths (78%) had undergone tumor-directed surgery within a year of diagnosis, 38% had undergone radiotherapy, and 46% had undergone chemotherapy. The distributions of all of the socio-demographic and clinical variables varied significantly by smoking status (Table 1) . There were 4491 cancer-specific deaths during the 5 years after diagnosis. The cumulative incidence of cancer-specific death was highest in current smokers and lowest in never smokers (Supporting Fig. 1a) . For non-cancer-related deaths, the cumulative incidence was higher in current and ex-smokers than in never smokers (Supporting Fig. 1b) .
Among all patients, in the univariate analysis, compared with never smokers, ex-smokers had a modest but nonsignificant increased hazard, whereas current smokers had a significantly increased hazard (Table 2 ). After adjustment for significant prognostic factors, current smokers still had a significantly raised rate of cancer death (multivariable HR, 1.15; 95% CI, 1.06-1.24). The hazard in ex-smokers was close to unity (HR, 1.02; 95% CI, 0.93-1.11). Effect modification analyses are shown in Supporting Table 3 . A significantly increased rate of cancer death among current smokers compared with never smokers was evident for men (multivariable HR, 1.13; 95% CI, 1.02-1.24) but not women (HR, 1.05; 95% CI, 0.90-1.23). The test for interaction was not statistically significant (P 5 .75). Similarly, there was a significant association between current smoking and cancer death in locoregional disease (multivariable HR, 1.18; 95% CI, 1.06-1.32) but not metastatic disease, but the test for interaction was not significant (P interaction 5 .12). There was no evidence of any interactions between smoking and age at diagnosis (P interaction 5 .76), treatment receipt (tumor-directed surgery, P interaction 5 .93; radiotherapy, P interaction 5 .69; chemotherapy, P interaction 5 .64) or period of diagnosis (P interaction 5 .78)
Sensitivity Analyses: Complete Case Dataset
Supporting Table 4 shows the characteristics of the 6829 patients in the complete case analysis. In univariate analyses, current smokers had a 23% higher rate of cancerspecific death than never smokers, but this was attenuated after adjustment (multivariable HR, 1.08; 95% CI, 0.99-1.18; Supporting Table 5 ).
Sensitivity Analyses: Competing Risks Regression
In the imputed dataset, the multivariable HRs for rectal cancer deaths, treating other causes as competing risks, were 1.15 (95% CI, 1.06-1.25) and 1.03 (95% CI, 0.95-1.13) for current and ex-smokers, respectively. The results for the complete case dataset were similar (data not shown).
DISCUSSION
In this population-based cohort study-by far the largest study to date on smoking and rectal cancer survival-we found a significantly increased rate of cancer-specific death in the 5 years after diagnosis in current versus never smokers. There was a suggestion that the association was limited to, or stronger in, men, but it did not differ between older and younger patients or by receipt of surgery, radiotherapy, or chemotherapy. The detrimental effect of smoking was limited to current smokers; in general, exsmokers did not have a higher cancer-specific death rate than never smokers.
Although significant, the magnitude of the association between smoking at the time of diagnosis and survival was relatively modest, and the effect size was smaller than reported in some other studies (although the risk estimates in these studies were not always statistically significant). 10, 12, 13 Our study was population-based, so there was no possibility of selection or participation of patients with particular patterns of smoking exposure. Unlike other studies, we adjusted for deprivation, which is a marker of socio-economic status. In many populations, including Ireland, smoking is more common in lower socioeconomic groups and/or more deprived areas. 28 In addition, deprivation and lower socio-economic status have been negatively associated with rectal cancer survival, 2 so this adjustment would be expected to attenuate the observed risk estimate for smoking.
The slightly stronger association with current smoking in males than females is broadly consistent with findings elsewhere; 2 colorectal cancer survival studies reported that the association was limited to males 15, 16 and a rectal cancer study found a significant association between current smoking and mortality only in males. 13 Almost twice as many rectal cancers were diagnosed in males than in females in Ireland between 1994 and 2012 and, among cases (as in the general population 29 ) current smoking prevalence was higher in men (28% versus 19%). Thus, similar to other studies, our study will have had less statistical power to detect modest associations in women than men. Studies suggest that men may be more likely to deny smoking than women, 30, 31 so the true difference in the hazard by sex may be greater than observed. In terms of explanations, men start smoking earlier and smoke more cigarettes on average, 32 likely resulting in higher cumulative exposure by diagnosis; they may be more likely to continue smoking after diagnosis than women; 33 and they may be more often exposed to other lifestyle factors (eg, obesity, unhealthy diet, high alcohol intake, lower physical activity), which are associated both with smoking and poorer survival/higher mortality from colorectal cancer. 14, [34] [35] [36] The evidence that smoking adversely affects postsurgical outcomes in colorectal cancer (including complications, 18 wound healing, 17 and 30-day mortality 9 ) suggests that smoking might be particularly detrimental for survival among patients who undergo surgery. In fact, we found no evidence for this: the HRs for current versus never smokers were almost identical in the surgery and nonsurgery groups. However, there are challenges in interpreting analyses comparing surgery and nonsurgery groups, because patients who die soon after diagnosis have no possibility of undergoing surgery. We undertook a landmark post hoc analysis in the multiple imputed dataset, restricting consideration to patients alive 6 months after diagnosis; the HRs for current versus never smokers were the same among surgical (multivariable HR, 1.10; 95% CI, 0.97-1.24) and nonsurgical patients (multivariable HR, 1.10; 95% CI, 0.91-1.33).
Mechanisms
The mechanisms by which smoking might affect rectal cancer survival are not understood. Smokers are more likely to have comorbid conditions; these might adversely impact survival among current smokers either directly (eg, by increasing risk of complications after surgery) or indirectly (eg, by influencing treatment receipt). Information is lacking on whether smoking is associated with recurrence, distant metastases, or second primaries in rectal cancer. In terms of genetic and epigenetic effects, smoking is related to increased DNA damage and reduced repair capacity, 37 and polymorphisms in DNA repair genes have been associated with colorectal cancer survival. 38 Similarly, smoking can induce aberrant DNA methylation, 39 and differential methylation has been associated with rectal cancer recurrence and survival. [40] [41] [42] However, whether smoking, DNA repair or methylation, and rectal cancer survival are interrelated remains unknown.
Smoking also affects inflammatory response 43 and immune competence. 44 An inflammation-related pathway has been implicated in rectal cancer aetiology; 45 systemic inflammatory response predicts outcome in rectal patients undergoing neo-adjuvant chemoradiation; 46 and presurgical inflammatory score may be a prognostic factor following colorectal resection. 47 However, interrelationships between inflammatory markers and smoking in predicting rectal cancer survival do not appear to have been investigated.
Strengths and Limitations
The size and population-basis are major strengths of the study. Because information was derived from routine medical records, smoking status was unknown for 23% of patients. Using multiple imputation to populate missing data generates effect estimates likely to be less biased than those resulting from other approaches for dealing with missing data. Morrison et al. 10 suggested that reverse causality may affect associations between smoking and rectal cancer mortality, because smokers may quit shortly before diagnosis due to symptoms. This could explain why the prevalence of current smoking in rectal cancer patients (25%) was lower than in the general population in Ireland in 2003 (men, 30%; women, 27%). 29 In addition, some current smokers may have been recorded in their medical records as never smokers; if so, we will have underestimated the true effect of smoking at diagnosis on cancerspecific mortality. However, the limited available data suggest a high correspondence between self-reported smoking status and biochemical measures among newly diagnosed cancer patients. 48 We lacked information on duration and intensity of tobacco exposure, whether smoking status changed after diagnosis, and on comorbidities, which are likely to be more common among smokers. 49 The use of cancer-specific survival was intended to account for deaths due to smoking-related comorbidities. While a considerable proportion of death certificates may be inaccurate, 50 there does not appear to be any published data on whether accuracy is differential by smoking status, or whether deaths from smoking-related conditions (such as chronic obstructive pulmonary disease) in cancer patients tend to be misattributed to cancer. Because competing risks can be a concern in cause-specific survival analysis, it was reassuring that the results of the competing risk regression sensitivity analysis were consistent with those of the cause-specific analysis. Moreover, although survival methods that are not dependent on the accuracy of cause of death are available, these also have limitations. 51 Finally, inadequate ascertainment of treatments could diminish true differences between the treatment strata. Although the overall use of radiotherapy appeared low, it was higher among patients who had rectal tumors compared with patients who had rectosigmoid tumors and increased over time (between 2007 and 2012) to a level consistent with figures from the American College of Surgeons' National Cancer Database. 52 Similar observations apply to chemotherapy. Thus, any misclassification is likely to be modest.
Conclusions
This large, population-based, study found that rectal cancer patients who smoke at diagnosis have a statistically significant increased rate of death from cancer. This effect may be limited to, or stronger in, men. Elucidation of the mechanisms underlying this association is urgently required. Meanwhile, greater efforts to support smoking cessation in individuals who are at risk of-and diagnosed with-rectal cancer would be beneficial. 
